ATLL, CLL and DLBCL
Cobomarsen Actively Recruiting for ATLL, CLL and DLBCL in the United States
➤ A Phase 1 clinical trial, MRG106-11-101, designed to evaluate the safety and tolerability of the investigational drug, cobomarsen (MRG-106).
Cobomarsen is an inhibitor of microRNA-155. microRNA-155 plays a role in the proliferation and survival of malignant cancer cells in certain types of blood cancer.
The Phase 1 trial of MRG-106 is currently being conducted in patients suffering from ATLL, CLL and DLBCL to study whether cobomarsen may inhibit the growth of these types of blood cancer. In addition to assessments of safety and tolerability, the trial will also assess pharmacokinetics.
More information on this study can be found here.
More information on cobomarsen can be found here.